{"tool_name":"tide","contents":["biotools","bioschemas"],"fetched_metadata":{"biotools":{"id":"tide","home":"http://tide.dfci.harvard.edu","summary":"Large-scale public data reuse to model immunotherapy response and resistance.\n\nTumor Immune Dysfunction and Exclusion (TIDE).\n\nWe validated TIDE performance on predicting anti-PD1 and anti-CTLA4 response across several melanoma datasets and a limited dataset of non-small cell lung cancer (NSCLC). TIDE may not work on cancer types other than melanoma and NSCLC (e.g., glioblastoma, or renal cell carcinoma) and therapies other than anti-PD1 and anti-CTLA4 (e.g., anti-PDL1, or Car T).","addition_date":"2021-01-18T07:41:41Z","last_update_date":"2021-02-27T09:33:32Z"},"bioschemas":{"name":"TIDE","home":"https://bio.tools/tide","summary":"Large-scale public data reuse to model immunotherapy response and resistance.\n\nTumor Immune Dysfunction and Exclusion (TIDE).\n\nWe validated TIDE performance on predicting anti-PD1 and anti-CTLA4 response across several melanoma datasets and a limited dataset of non-small cell lung cancer (NSCLC). TIDE may not work on cancer types other than melanoma and NSCLC (e.g., glioblastoma, or renal cell carcinoma) and therapies other than anti-PD1 and anti-CTLA4 (e.g., anti-PDL1, or Car T).","tool_type":"sc:SoftwareApplication"}}}